Posted in | News | Business

BHP Billiton's Merger with Rio Tinto Receives Clearance

BHP Billiton today welcomed the decision by the Australian Competition and Consumer Commission that it does not object to BHP Billiton's proposed acquisition of Rio Tinto.

"We are very pleased to have received notice that the ACCC will not object to our proposed acquisition of Rio Tinto.

"We have long believed in the benefits of the combination of BHP Billiton and Rio Tinto. Our strategic rationale has always been based on the combined company having an incentive to produce more product, more quickly, to deliver to customers." BHP Billiton's Chief Commercial Officer, Alberto Calderon, said.

Confirmation that the ACCC does not object satisfies the Australian merger control pre-condition of BHP Billiton's proposed offer for Rio Tinto. In July, the U.S. Department of Justice also announced it would not oppose the transaction. The offer remains subject to the pre-conditions as disclosed in Appendix 1 of the announcement on 6 February 2008.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BHP. (2019, March 18). BHP Billiton's Merger with Rio Tinto Receives Clearance. AZoM. Retrieved on April 25, 2024 from https://www.azom.com/news.aspx?newsID=13952.

  • MLA

    BHP. "BHP Billiton's Merger with Rio Tinto Receives Clearance". AZoM. 25 April 2024. <https://www.azom.com/news.aspx?newsID=13952>.

  • Chicago

    BHP. "BHP Billiton's Merger with Rio Tinto Receives Clearance". AZoM. https://www.azom.com/news.aspx?newsID=13952. (accessed April 25, 2024).

  • Harvard

    BHP. 2019. BHP Billiton's Merger with Rio Tinto Receives Clearance. AZoM, viewed 25 April 2024, https://www.azom.com/news.aspx?newsID=13952.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.